Although the lack of cross-reactive mAbs has hampered the full characterization of the autoaggressive IL-17+ve CTL that drive the progression pathway in marmoset EAE, the available evidence suggests that they may be related to or even identical with CD8+ CD161+ CD28− NK-CTL present in the human anti-CMV T cell repertoire; a similar T cell type has been implicated in MS (111). Here, CD28 is linked to myeloid sarcoma.